Literature DB >> 33662481

Comparison of Ellipsys Percutaneous and Proximal Forearm Gracz-Type Surgical Arteriovenous Fistulas.

Robert Shahverdyan1, Gerald Beathard2, Nasir Mushtaq3, Terry F Litchfield4, Shant Vartanian5, Klaus Konner6, William C Jennings7.   

Abstract

RATIONALE &
OBJECTIVE: Percutaneous arteriovenous fistulas (AVF) are created by establishing a proximal forearm anastomosis and offer a safe and reliable vascular access. This study compares the Ellipsys percutaneous AVF with a proximal forearm Gracz-type surgical AVF, chosen for comparison as it is constructed at the same anatomical site. STUDY
DESIGN: Retrospective study of prospectively collected clinical data. SETTING & PARTICIPANTS: All vascular access procedures conducted during a 34-month period were reviewed. The study groups comprised 89 percutaneous AVFs and 69 surgical AVFs. EXPOSURE: Percutaneous or surgical AVF placement. OUTCOME: AVF patency, function, and complications. ANALYTICAL APPROACH: Patency rates for each AVF group were evaluated by competing risk survival analysis using a cumulative incidence function. Association of primary, primary assisted, and secondary patency with the AVF groups was examined by Cox proportional hazard models.
RESULTS: Technical success was 100% for both groups. Average procedure times were 14 minutes for percutaneous AVFs and 74 minutes for surgical AVFs (P < 0.001). Proximal radial artery (PRA) was used in all percutaneous AVF cases. Inflow for surgical AVFs included radial (30%), ulnar (12%), and brachial (58%) arteries. Outflow veins for both groups were the cephalic and/or basilic veins. Access flow volumes, times to maturation, and overall numbers of interventions per patient-year were not significantly different. Cumulative incidence of primary patency failure at 12 months was lower for surgical AVF (47% vs 64%, P = 0.1), but secondary patency failure was not different between groups (20% vs 12%, P = 0.3). PRA surgical AVFs had similar primary patency (65% vs 64%, P = 0.8) but higher secondary patency failure rates than percutaneous AVFs at 12 months (34% vs 12%, P = 0.04). LIMITATIONS: Retrospective study with a relatively short follow-up period, and not all patients required hemodialysis at the end of study.
CONCLUSIONS: Both percutaneous and surgical AVFs demonstrated high rates of technical success and secondary patency. Percutaneous AVFs required shorter procedure times. The rate of intervention was similar. When a distal radial artery AVF is not feasible, percutaneous AVF might offer an appropriate procedure for creating a safe and functional access, maintaining further proximal forearm surgical AVF creation options.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arteriovenous fistula (AVF); access creation; dialysis access surgery; end-stage kidney disease (ESKD); endovascular; hemodialysis access; maturation; patency; percutaneous; surgical; vascular access

Year:  2021        PMID: 33662481     DOI: 10.1053/j.ajkd.2021.01.011

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  4 in total

1.  Vascular Suitability for an Endovascular Arteriovenous Fistula: Getting Beyond the Velvet Rope.

Authors:  Haimanot Wasse
Journal:  Kidney360       Date:  2022-02-24

Review 2.  A Comparison Between the Efficacy and Safety of Endovascular Arteriovenous Fistula Creation and Surgical Fistula Creation: A Systematic Review and Meta-Analysis.

Authors:  Yoshinosuke Shimamura; Yasutaka Kuniyoshi; Hiroshi Ueta; Takamasa Miyauchi; Hajime Yamazaki; Yasushi Tsujimoto
Journal:  Cureus       Date:  2022-05-17

3.  Endovascular Versus Surgical Arteriovenous Fistulas: A Systematic Review and Meta-analysis.

Authors:  Muhammad Hammad Malik; Marwa Mohammed; David F Kallmes; Sanjay Misra
Journal:  Kidney Med       Date:  2021-12-29

4.  Percutaneous endovascular arteriovenous fistula: A systematic review and meta-analysis.

Authors:  Ji-Bo Sun; Chun-Cheng Liu; Xi Shen; Qin Chen; Cheng-Liang Xu; Tian-Lei Cui
Journal:  Front Cardiovasc Med       Date:  2022-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.